Amir Safavi

In @JCO_ASCO, our reflections on the timely ASCO TORS guideline @imrtlee @xrtGenomics 💡Encourage MR (r/o T4+ENE) & PET (r/o contra in N+) 💡Promote ND qual (min # nodes), ⬇️ bilat ND (morbid) 💡Caution re: ❌chemo 2/2 ENE degree & real-world use of frozens re margin status

1/ Just published in @IJROBP: “Histological Classifier of Radiosensitivity to Spine SBRT.” doi.org/10.1016/j.ijro…

We are excited that our most recent amendment was approved, streamlining imaging criteria for enrollment. EA3211 is a phase III randomized trial comparing consolidative radiotherapy plus pembro with pembro alone in patients with oligometastatic head and neck cancer who have not…

Felson’s 10 axioms for a lifetime of learning in medicine

This study and pathologic staging proposal are very well done. It fixes a major problem in the current AJCC 8 pathologic staging for p16 OPSCC, which is a profound imbalance in staging (towards stage I). The updated system essentially uses ENE to help further break down the…

There is one major caveat here, which is that the study is all based on the NCDB. Thus, the definition of ENE is dependent on a large database without (to my knowledge) validation of the ENE variable. The odd 2 mm threshold (versus 1 mm from EA3311) is based on how NCDB coded…

We ❤️ seeing Comprehensive Motion Management bring certainty to the treatment of targets impacted by motion. Today at 11:56 in room 202, Neelam Tyagi will present @MSKCancerCenter's experience using CMM, as well as advancements in OART with Unity bit.ly/4lGo1Kg #AAPM2025

Life is better with science, cats, and a bit of inhibition!

In this #WorldHeadandNeckCancerDay Resharing my story in the hope that people newly diagnosed know there are treatment options. @RTAnswers_org rtanswers.org/survivorship/p…

Tislelizumab plus nab-paclitaxel and cisplatin as induction immunochemotherapy for organ preservation of locally advanced hypopharyngeal SCC: a single-arm ph II trial in @ESMO_Open. 86.7% 3-months larynx preservation rate with 21.4% pCR rate. esmoopen.com/article/S2059-…

Although obtaining a post-op PET/CT has inherent challenges (e.g., insurance hurdles, confounding surgical inflammation), we still find that obtaining the scan is quite helpful and can change management in over 40% of cases, most often in delineating targets in post-op RT.

Good trials beget good trials! RTOG 1112 ➡️ GI012 (HELIO-RT) ☢️ @ldawsonmd Dr. Jennifer Wo @MassGenBrigham Let’s keep our seats at the HCC table & enroll our pts: BCLC Class C w/ MVI! @NRGonc @RTOGFoundation

What a fruitful way to spend a Sat AM with #HeadNeckCancer experts discussing about #OralCavity cancers Thanks to @DrGopalIyer Prof Sarbani from @TataMemorial for the lectures! And @ASCO for the support of the #MultidisciplinaryCancer #MCMC course for Sarawak General Hospital!

Great to be in DC today @NRGonc giving an update on the progress of #HN014 #C-PRE for patients with advanced, resectable #skin #CSCC cancer. >100 sites activated in the US alone and accrual 🚀@NCICancerCtrl @TROGfightcancer @CDNCancerTrials @Regeneron #OncSurgery @MDAndersonNews

Very fond of this practice and complements the paper from @yaoyu_md @imrtlee and @MSKCancerCenter #hncsm team

I recently saw a patient 9 years following early-stage glottic larynx SAbR (on our original CyberKnife trial). The images below represent the typical endoscopic appearance. Our G-FORCE phase II RCT (LT-SAbR versus whole larynx) is now ~ 33% accrued! clinicaltrials.gov/study/NCT06080…

T cells do the heavy lifting when it comes to the anti-tumor action of checkpoint immunotherapy. But do antibodies play a role too? That’s the question @yile_dai looked to answer in his thesis work, out today in @Nature! 🧵below nature.com/articles/s4158…

1/14 When I was 14 years old, soccer was everything to me. I wasn’t the best player, but I prided myself on my endurance. In the fall of 2005, I started becoming winded very easily.

🎉 Just announced: A huge congrats to #RMPatPM staff @ScottBratman @CJTsaiMDPhD Dr. Philip Wong @DKirschMDPhD @MKoritzinsky who received over $3.5 million in @CIHR_IRSC funding for their cutting-edge radiation research. See highlights below⤵️

Thanks to @QuadShotNews for featuring our manuscript

Want a Sunday morning reading with a sip of coffee? Here is one (in press) for #PCSM enthusiasts! sciencedirect.com/science/articl… Always grateful for the support and motivation from @DrSpratticus even during tough times and @yilun_sun for teaching me new things every time!!